Clinical Validity of 16α-[ 18 F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.
Jasper J L van GeelJorianne BoersSjoerd G EliasAndor W J M GlaudemansErik F J de VriesGeke A P HospersMichel van KruchtenEvelien J M KuipAgnes JagerCatharina Willemien Menke-van der Houven van OordtBert van der VegtElisabeth G E de VriesCarolina P Schrödernull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
F]FES-PET, this noninvasive imaging modality can be considered a valid alternative to a biopsy of a metastasis to determine ER status in newly MBC (ClinicalTrials.gov identifier: NCT01957332).